Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis

被引:0
作者
John H. Baird
Jason Gotlib
机构
[1] Stanford Cancer Institute / Stanford University School of Medicine,Division of Hematology
来源
Current Hematologic Malignancy Reports | 2018年 / 13卷
关键词
Systemic mastocytosis; KIT D816V; Midostaurin; Avapritinib; Imatinib;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:407 / 416
页数:9
相关论文
共 640 条
[1]  
Arber DA(2016)The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 127 2391-2405
[2]  
Orazi A(2009)Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors Blood 113 5727-5736
[3]  
Hasserjian R(2009)Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients J Allergy Clin Immunol 124 514-521
[4]  
Thiele J(2009)Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies Blood 114 3769-3772
[5]  
Borowitz MJ(2010)WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults Blood 115 150-151
[6]  
Le Beau MM(2013)Mast cell leukemia Blood 121 1285-1295
[7]  
Lim K.-H.(2010)Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature Curr Opin Hematol 17 125-132
[8]  
Tefferi A.(2015)KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis Leukemia 29 1223-1232
[9]  
Lasho T. L.(2001)Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis British Journal of Haematology 113 357-364
[10]  
Finke C.(2006)KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients Blood 108 2366-2372